Zynex (NASDAQ:ZYXI) Reports Quarterly Earnings, Missing Estimates by $0.04 Per Share

Zynex (NASDAQ:ZYXI – Get Free Report) reported its quarterly earnings on Thursday. The company reported earnings per share of $0.04 for the quarter, which was $0.04 below the consensus estimate of $0.08, Briefing.com reported. Zynex had a return on equity of 13.14% and a net margin of 3.12%. The company had revenue of $49.88 million during the quarter, compared to analyst estimates of $51.99 million. In the same quarter last year, the company posted EPS of $0.09. Zynex’s quarterly revenue increased 11.0% compared to the same quarter last year.

Zynex Price Performance

NASDAQ ZYXI stock opened at $8.93 on Friday. The stock has a market cap of $283.71 million, a price-to-earnings ratio of 38.83, and a beta of 0.53. Zynex has a 12-month low of $6.88 and a 12-month high of $13.77. The company’s 50-day simple moving average is $9.55 and its 200-day simple moving average is $11.06. The company has a debt-to-equity ratio of 1.76, a current ratio of 3.58, and a liquidity ratio of 2.87.

Wall Street analysts’ opinion

Several equity analysts have recently weighed in on ZYXI’s stock. HC Wainwright lowered their price target on shares of Zynex from $21.00 to $16.00 and gave the stock a buy rating in a report on Friday. Royal Bank of Canada lowered their price target on shares of Zynex from $15.00 to $12.00 and gave the stock an outperform rating in a report on Friday.

Check out our latest research report on ZYXI

Zynex Company Profile

(Get a free report)

Zynex, Inc. and its subsidiaries design, manufacture and market medical devices to treat chronic and acute pain and to activate and exercise muscles for rehabilitation using electrical stimulation. The Company offers NexWave, a dual-channel, multimodality transcutaneous electrical nerve stimulation and neuromuscular electrical stimulation (NMES) device, marketed to physicians and therapists through field sales representatives; NeuroMove, an electromyography and electrical stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device.

See also

Get daily news and reviews for Zynex – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Zynex and associated companies with MarketBeat.com’s FREE daily e-newsletter.